APA (7th ed.) Citation

K, G., MJ, K., RR, C., S, E., Z, Z., M, D., . . . SP, C. (2025). Utilization of patient-reported outcomes to assess adherence to relugolix when combined with stereotactic body radiation therapy for intermediate to high-risk prostate cancer. Frontiers in oncology, 15, 1540482. https://doi.org/10.3389/fonc.2025.1540482

Chicago Style (17th ed.) Citation

K, Gaudian, et al. "Utilization of Patient-reported Outcomes to Assess Adherence to Relugolix When Combined with Stereotactic Body Radiation Therapy for Intermediate to High-risk Prostate Cancer." Frontiers in Oncology 15 (2025): 1540482. https://doi.org/10.3389/fonc.2025.1540482.

MLA (9th ed.) Citation

K, Gaudian, et al. "Utilization of Patient-reported Outcomes to Assess Adherence to Relugolix When Combined with Stereotactic Body Radiation Therapy for Intermediate to High-risk Prostate Cancer." Frontiers in Oncology, vol. 15, 2025, p. 1540482, https://doi.org/10.3389/fonc.2025.1540482.